Lithium augmentation in venlafaxine non-responders: an open study.
Thirteen major depressive patients not responding to a 4-week venlafaxine 300 mg treatment were eligible for a 4-week open trial of lithium addition. Two patients had to stop lithium for a possible moderate serotonin syndrome and five patients became responders, including one dramatic response and two semi-rapid responses.
Bertschy
G
G
Clinic of Adult Psychiatry, Department of Psychiatry, Geneva University, 2 ch. du Petit Bel-Air, Chene-Bourg, 1225 Geneva, Switzerland. gilles.bertschy@hcuge.ch
Ragama-Pardos
E
E
Aït-Ameur
A
A
Muscionico
M
M
Favre
S
S
Roth
L
L
D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003511:Cyclohexanols / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D018020:Lithium Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D013431:Sulfates / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
D000928:Antidepressive Agents; D003511:Cyclohexanols; D003692:Delayed-Action Preparations; D018020:Lithium Compounds; D013431:Sulfates; D000069470:Venlafaxine Hydrochloride; C054097:lithium sulfate